SCHEDULE: BlackRock Discloses 6.6% Stake in Oruka Therapeutics

BlackRock, Inc. has reported a 6.6% beneficial ownership stake in Oruka Therapeutics, Inc., holding 3,175,483 shares of common stock as of December 31, 2025.

Summary

• BlackRock, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in Oruka Therapeutics, Inc.
• As of December 31, 2025, BlackRock beneficially owns 3,175,483 shares of Oruka Therapeutics, Inc. common stock.
• This represents 6.6% of the total outstanding common stock of Oruka Therapeutics, Inc.
• BlackRock holds sole voting power over 3,128,050 shares and sole dispositive power over 3,175,483 shares.
• The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• BlackRock acts as a parent holding company, with various subsidiaries holding the securities, including BlackRock Advisors, LLC and BlackRock Fund Advisors, one or more of which beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant, passive stake by a major institutional investor like BlackRock is generally viewed positively as it implies confidence in the company's long-term prospects, even if it's a routine investment for BlackRock. There are no negative elements in the filing itself.

Positives

• A significant institutional investor like BlackRock holding a 6.6% stake can be seen as a vote of confidence in Oruka Therapeutics, Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a standard investment strategy rather than an activist position, implying stability.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance regarding Oruka Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the current stake.

Management Comments

• The filing includes a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Oruka Therapeutics, Inc.

Industry Context

This filing reflects a standard disclosure by a major institutional asset manager, BlackRock, Inc., indicating a significant, passive investment in a biotechnology company. Such filings are common for large funds that manage assets across a broad portfolio, including emerging companies like Oruka Therapeutics, Inc. It signals BlackRock's presence as a long-term, passive holder in the sector.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership by a large institutional investor. It does not contain performance metrics of Oruka Therapeutics, Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The 6.6% stake by BlackRock is a notable position for a single institutional investor in a company, aligning with typical large fund management strategies to hold diversified, passive stakes in publicly traded entities.

Stakeholder Impact

• Shareholders: May view BlackRock's significant stake as a positive signal, potentially increasing investor confidence and liquidity.
• Management: The passive nature of the stake suggests BlackRock is not seeking to influence control, allowing current management to continue their strategic direction without immediate pressure from this specific investor.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Oruka Therapeutics, Inc. or BlackRock's investment strategy.

Key Dates

Recommendation

The filing indicates a significant, passive stake by a major institutional investor, BlackRock, Inc., which can be interpreted as a vote of confidence in Oruka Therapeutics, Inc. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The 'hold' recommendation reflects the stability implied by a large institutional investor's passive stake, suggesting no immediate catalyst for a change in investment strategy based solely on this ownership disclosure.

Keywords

Oruka Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals, Investment